CRMD - CorMedix Inc Market Cap to Sales Volume

Recurring Defencath sales in dialysis centers provide CorMedix Inc. (CRMD) with a steady stream of free cash flow. Business flexibility is maintained by outsourcing production and research to external contractors. The company's P/S ratio dynamics clearly confirm the current valuation, where 0.90 records a new level. This approach renders the asset defensive, as demand for medical innovation remains independent of macroeconomic crises.

CorMedix Corp (CRMD): Price-to-Revenue Ratio from 07/04/2022 to 11/14/2026

Metric breakdowns and analytics for CorMedix Corp (CRMD)

- market price and analyst price targets:

Stock Quotes cormedix.com|CRMD - Consensus Target

- market capitalization statistics:

Market Value CorMedix Corp|CRMD - Enterprise Value

- book capitalization information:

Net Assets per Share CorMedix|CRMD - Company Book Value|Market-to-Book Ratio cormedix.com|CRMD - Aggregate Company Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

CRMD - Company Net Income|Future Profit CorMedix Inc.|CRMD - P/E Multiple|Projected Price to Earnings Ratio CorMedix Inc|CRMD - PEG Multiple|Enterprise Value to Operating Income Before Depreciation CorMedix Corp|CRMD - Operating profit EBITDA|Net earnings per share for the last four quarters CorMedix|CRMD - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months cormedix.com|CRMD - Net earnings per share growth this year|Expected earnings per share trend next year CorMedix Inc.

- total revenue and sales volume data:

CRMD - Revenue and Sales Volume|Company Future Sales cormedix.com|CRMD - Price-to-Revenue Ratio|Market Cap to Projected Revenue CorMedix Corp

General company analysis:CRMD (cormedix.com)

The P/S multiple determines the market value of a business relative to its annual revenue, allowing an investor to assess the premium paid per unit of generated income. The price-to-sales ratio trend reflects market expectations for the expansion of CorMedix Inc. (CRMD), whose strong pricing power in the infection prevention segment and lack of competitors justify the potential for capitalization growth as sales scale.

Competitors of CorMedix Inc.